Episodit
-
EY’s John Babbitt and Jim Welch join us for this episode to dive deeply into the Pulse of the Medtech Industry Report. We’re talking about deals, IPOs, the hottest segments, and more in this incredible episode of Let’s Talk Medtech.
-
Interested in designing medical device products? Want to know the do's and dont's of medtech design? Then you must listen to this all-new episode of Let's Talk Medtech featuring BlackHägen Design's Philip Remedios and Renee Bailey. Both will talk about what you need to have in mind when building device and breakdown how Contextual Inquiry is changing how we think about medtech design.
-
Puuttuva jakso?
-
Upma Sharma joins us for this episode of Let's Talk Medtech to discuss how Arsenal Medical is developing biomaterials that are changing the way medicine is practiced. Sharma also discusses her evolution from a researcher to CEO of a medtech company.
-
Scott Nelson, one of the medical device's top insiders, stops by to discuss the trends in the industry and to give tips to entrepreneurs looking to jump into the world of medtech. Nelson is the co-founder and CEO of FastWave Medical, a medical device startup developing intravascular lithotripsy systems for cardiovascular disease. Additionally, he’s the founder of Medsider, where he interviews founders and CEOs of promising, early-stage medical device and health technology companies.
-
Dana Brown, iCAD's president, chairman and CEO, shares how the company is changing the way we think about breast cancer detection. Brown gives us an update on the partnership with Google. Plus, she talks about her time at Susan G. Komen and how cancer detection has changed throughout the years. She also gives some tips for aspiring medtech professionals in this new episode of Let's Talk Medtech.
Omar : How are you?
Dana: Great. Thanks for having me.
Omar: I'm doing well, just a bit sleep-deprived with a newborn at home, but otherwise, all good.
Dana: Congratulations.
Dana: Thank you. So, Dana, it's been over a year since you took the reins at iCAD. How has the journey been so far?
Dana: Better than I expected, honestly. I joined ICAD's board over two years ago, initially thinking it was my dream role. But I saw an opportunity to contribute more directly given my background in cloud technologies and breast health. Jumping in has been fantastic—the team is great, and seeing our solutions in action, not just on paper, has been incredibly rewarding.
Omar: That's wonderful to hear. Before we dive into iCAD, let's talk about your time at Susan G. Komen. Can you share about your role there?
Dana: Sure, at Susan G. Komen, I served as the chief strategic and operations officer for nearly five years. My focus was enhancing direct patient engagement, ensuring initiatives like helplines, financial aid, and support resources were impactful and accessible. It was about making sure Komen's efforts directly benefited patients throughout their breast cancer journey.
Omar: How have your experiences at Komen influenced your approach at iCAD?
Dana: Three main takeaways: continuous learning, particularly in management and collaboration; leveraging technology like EMRs and research registries to enhance patient care; and fostering a culture of innovation, crucial for developing effective solutions in breast health.
Omar: It sounds like a wealth of knowledge to bring to iCAD. Speaking of which, let's touch on iCAD's use of AI in breast cancer detection. How is AI reshaping mammography?
Dana: AI has revolutionized mammography by enhancing accuracy and efficiency. Unlike human eyes, AI processes data at a granular level, making it a reliable second opinion for radiologists. Beyond cancer detection, we're exploring applications like detecting breast arterial calcification, offering a more holistic view of a patient's health.
Omar: That's impressive—AI as a precision tool in healthcare. Is it making mammogram results more understandable for patients?
Dana: Currently, AI primarily aids clinicians by providing trusted decision support. However, patients are becoming aware of AI's role and its potential to offer them clearer, faster insights into their health—a promising development we're exploring further.
Omar: Moving forward, iCAD has partnered with Google Health. What can you tell us about this collaboration?
Dana: Our collaboration with Google Health spans two key initiatives: integrating our technology into Google's cloud infrastructure for seamless healthcare operations, and jointly developing advanced AI algorithms. This includes creating an AI-powered second reader for mammograms, aiming to streamline diagnosis and reduce turnaround times, addressing the shortage of radiologists globally.
Omar: That's a significant step forward in leveraging technology for healthcare efficiency. While we await regulatory clearances, how do you see AI influencing patient care in the future?
Dana: AI is empowering patients with knowledge and enabling more informed healthcare decisions. It's part of a broader trend towards patient empowerment, where individuals actively engage in their health management—a positive shift we're committed to advancing at ICAD.
Omar: Your...
-
European Union states greenlit a measure to regulate artificial intelligence. The sweeping law is the first of its kind and will have a definitive impact on any companies that employ the use of AI.
Anne-Gabrielle Haie, a partner with Steptoe LLP, answers questions about the AI Act and discusses its potential impact on the medical device industry in this all-new episode of Let's Talk Medtech.
-
MD&M West is a tradeshow that boasts some of the best speakers in the medical device industry - and Let's Talk Medtech has snagged its keynote speaker, Jennifer Samproni for this can't miss episode.
Jennifer is the Chief Technology Officer, of Health Solutions at Flex, and drops by to shed some light on her keynote speech - Transforming the Future of Patient Care with Human Machine Interfaces. She'll also talk about how artificial intelligence is changing healthcare; why contract manufacturing is booming; and give tips on navigating the medical device industry in this season opener of Let's Talk Medtech.
-
MD+DI's Senior Editor, Amanda Pedersen joins us for this episode of Let's Talk Medtech to look at what 2023 was for the medical device and diagnostics industry. The veteran journalist also dives into what the future might hold in 2024 for the industry.
-
Benjamin Zegarelli, counsel with Mintz, gives some important regulatory updates surrounding laboratory-developed tests, artificial intelligence, and software. Oh yeah, we talk about a little thing called EU MDR in this new episode of Let's Talk Medtech.
-
Surbhi Sarna began her journey into medtech when she had a health scare at the age of 13. The ordeal led her to founding nVision, a company focused on the detection of ovarian cancer. nVision was eventually acquired by Boston Scientific.
Sarna joins us shortly before her keynote at BIOMEDevice Silicon Valley to discuss her journey into medtech and what it takes to be an entrepreneur in the industry.
-
How is medtech holding up in this tough economy? Are supply issues still a problem in the industry? What's the next big market for growth? Is medtech still healthy? EY's Jim Welch answers these questions and talks about the company's latest Pulse of the Industry report in this brand-new episode.
-
GE HealthCare started off 2023 by becoming a fully independent company. The company then wasted little time making acquisitions. Most recently, GE HealthCare was in the spotlight because of developments in Alzheimer's treatments that could potentially drive up the demand for the firm's imaging equipment.
Jan Makela, President and CEO, of Imaging at GE HealthCare, joins us to talk about the company's success and how it plans to finish out the year, in this exciting new episode.
-
It's all about surgical robotics as AiM Medical Robotics, Founder & CEO Gregory Fischer, PH.D. joins us for this episode of Let's Talk Medtech. Dr. Fischer talks about the surgical robotics landscape and all of the cool things AiM Medical Robotics has been up to.
Plus, he gives a preview of his upcoming keynote at BIOMEDevice Boston titled, "From Concept to Commercialization: It’s not brain surgery, or is it?"
-
Claire Smith, VP of global strategic marketing for Nevro, shares how the company's HFX iQ technology is using artificial intelligence to help treat chronic pain. Smith also shares some of her experiences in medtech sales and how the role of a medtech salesperson has changed over the years.
-
It's been a little more than a year since ZimeVie was launched from Zimmer Biomet. The dental and spine specialist has had to overcome some tough obstacles and find its footing. ZimVie's CEO, Vafa Jamali returns to Let's Talk Medtech to discuss the company's growth, tribulations, success, and why Europe has become a fertile market. You don't want to miss this exciting episode of Let's Talk Medtech.
-
Nicole Black, Phd., Vice President of Biomaterials and Innovation, at Desktop Health, drops by to discuss how new technological developments are transforming 3D printing from a method primarily used for prototyping into a reliable manufacturing method for end-use medical devices. Black is also a keynote speaker at BioMEDevice Boston, an event showcasing emerging technologies and trends from the medtech market, set to be held Sept. 20-21 at the Boston Convention & Exhibition Center.
-
Naomi Schwartz, the Senior Director for Cybersecurity Quality & Safety at Medcrypt, a medical device cybersecurity specialty firm, shares some interesting tidbits about FDA's upcoming Refuse-to-Accept (RTA) policy for Cyber Devices and Related Systems. The policy is effective Oct. 1 and Schwartz breaks down what the RTA will mean for medical device manufacturers and their FDA submissions.
-
Rachel Hall, EY's US Consulting Digital Health and Smart Health Experience Leader, joins us for this episode as we peel back the layers of digital health.
Rachel will give her take on the landscape and how each player, patient, physician, and healthcare firm fit into the ecosystem.
We also talk about something that's been on everyone's minds lately - and that's artificial intelligence.
So join us for this episode of Let's Talk Medtech as we "crack" the digital health code.
-
Volta Medical is a company that has developed AI software solutions to assist cardiac electrophysiologists in treating atrial fibrillation (AF). Its technology focuses on mapping abnormal regions in the heart during AF procedures and providing cues to optimize the ablation strategy. Unlike other mapping technologies, Volta Medical takes a data-driven approach and aims to replicate the clinical expertise of physicians using machine learning and AI.
The company recently completed enrollment for the TAILORED-AF clinical trial, which is a large-scale international trial involving multiple centers and physicians in five countries. The trial enrolled 374 patients who will be followed up for one year. The primary endpoint is freedom from AF after one procedure, with several secondary endpoints related to freedom from arrhythmia.
The co-founder of Volta Medical, Theophile Mohr-Durdez, joins this episode of Let's Talk Medtech to talk about the company's technology, long-term goals, and the unique skillset he brings to the table thanks to his experience on stage.
-
Elucid is changing the way we think about cardiovascular health. To do this, the Boston-based company has appointed medtech veteran, Scott Huennekens as chairman of its board.
Scott along with Elucid's CEO Blake Richards joins us for this episode to talk about how the company is changing the way we view cardiovascular health.
Plus, Scott discusses his incredible career in this can't-miss episode.
- Näytä enemmän
